Rock Springs Capital Management LP Madrigal Pharmaceuticals, Inc. Transaction History

Rock Springs Capital Management LP

$1.67 Billion
Q1 2025

A detailed history of Rock Springs Capital Management LP transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Rock Springs Capital Management LP holds 166,698 shares of MDGL stock, worth $50 Million. This represents 3.3% of its overall portfolio holdings.

Number of Shares

166,698

Previous 265,212 37.15%

Holding current value

$50 Million

Previous $81.8 Million 32.53%

% of portfolio

3.3%

Previous 3.27%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$272.79 - $355.88 $26.9 Million - $35.1 Million	-98,514 Reduced 37.15%	166,698 $55.2 Million
Q4 2024 Feb 14, 2025	BUY	$202.45 - $354.85 $435,267 - $762,927	2,150 Added 0.82%	265,212 $81.8 Million
Q3 2024 Nov 14, 2024	BUY	$212.22 - $292.96 $3.73 Million - $5.15 Million	17,563 Added 7.15%	263,062 $55.8 Million
Q2 2024 Aug 14, 2024	SELL	$193.33 - $291.99 $7.82 Million - $11.8 Million	-40,432 Reduced 14.14%	245,499 $68.8 Million
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $15 Million - $24.9 Million	87,762 Added 44.29%	285,931 $76.4 Million
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $216,720 - $426,834	1,800 Added 0.92%	198,169 $45.9 Million
Q3 2023 Nov 14, 2023	SELL	$146.04 - $225.78 $416,067 - $643,247	-2,849 Reduced 1.43%	196,369 $28.7 Million
Q2 2023 Aug 14, 2023	SELL	$203.88 - $312.0 $30.4 Million - $46.5 Million	-148,903 Reduced 42.77%	199,218 $46 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $1.79 Million - $9.08 Million	30,636 Added 9.65%	348,121 $101 Million
Q2 2022 Aug 15, 2022	BUY	$58.04 - $100.2 $2.55 Million - $4.41 Million	43,985 Added 16.08%	317,485 $22.7 Million
Q1 2022 May 16, 2022	BUY	$55.89 - $101.89 $229,149 - $417,749	4,100 Added 1.52%	273,500 $26.8 Million
Q4 2021 Feb 14, 2022	BUY	$72.34 - $95.09 $499,146 - $656,121	6,900 Added 2.63%	269,400 $22.8 Million
Q2 2021 Aug 16, 2021	BUY	$97.2 - $137.59 $388,800 - $550,360	4,000 Added 1.55%	262,500 $25.6 Million
Q1 2021 May 17, 2021	BUY	$108.54 - $125.2 $187,991 - $216,846	1,732 Added 0.67%	258,500 $30.2 Million
Q4 2020 Feb 16, 2021	BUY	$110.06 - $133.7 $275,150 - $334,250	2,500 Added 0.98%	256,768 $28.5 Million
Q2 2020 Aug 14, 2020	BUY	$60.13 - $125.71 $256,634 - $536,530	4,268 Added 1.71%	254,268 $28.8 Million
Q1 2020 May 15, 2020	SELL	$66.76 - $93.49 $13,352 - $18,698	-200 Reduced 0.08%	250,000 $16.7 Million
Q4 2019 Feb 14, 2020	SELL	$84.28 - $118.5 $1.87 Million - $2.63 Million	-22,200 Reduced 8.15%	250,200 $22.8 Million
Q3 2019 Nov 14, 2019	BUY	$84.4 - $106.53 $1.31 Million - $1.65 Million	15,500 Added 6.03%	272,400 $23.5 Million
Q2 2019 Aug 14, 2019	BUY	$91.13 - $142.5 $150,364 - $235,125	1,650 Added 0.65%	256,900 $26.9 Million
Q1 2019 May 15, 2019	BUY	$103.48 - $143.84 $1.47 Million - $2.05 Million	14,250 Added 5.91%	255,250 $32 Million
Q4 2018 Feb 14, 2019	SELL	$94.77 - $215.54 $9.57 Million - $21.8 Million	-101,000 Reduced 29.53%	241,000 $27.2 Million
Q3 2018 Nov 14, 2018	SELL	$207.3 - $300.31 $62,190 - $90,093	-300 Reduced 0.09%	342,000 $73.2 Million
Q2 2018 Aug 14, 2018	BUY	$101.55 - $313.9 $1.71 Million - $5.27 Million	16,800 Added 5.16%	342,300 $95.7 Million
Q1 2018 May 15, 2018	SELL	$93.35 - $149.04 $1.54 Million - $2.46 Million	-16,500 Reduced 4.82%	325,500 $38 Million
Q4 2017 Feb 14, 2018	BUY	$39.35 - $97.37 $2.64 Million - $6.52 Million	67,000 Added 24.36%	342,000 $31.4 Million
Q3 2017 Nov 14, 2017	BUY	$15.48 - $46.19 $4.26 Million - $12.7 Million	275,000	275,000 $12.4 Million

Others Institutions Holding MDGL

# of Institutions

367

Shares Held

23.3M

Call Options Held

979K

Put Options Held

459K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.13B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.

Account

Rock Springs Capital Management LP Madrigal Pharmaceuticals, Inc. Transaction History